Histamine-Producing Intestinal Dysbiosis and Its Role in Lower Urinary Tract Infections and Irritable Bowel Syndrome in Young Women
by
, ,
Florina Ruța
1
,
Călin Avram
2,*,
Elena Mardale
3,*,
Raluca Maior
1,
Cristina Filip
4 and
Sebastian Nemeth
5 1
Department of Community Nutrition and Food Safety, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540139 Targu Mures, Romania
2
Department of Medical Informatics and Biostatistics, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540139 Targu Mures, Romania
3
Doctoral School of Biomedical Sciences, University of Oradea, 410087 Oradea, Romania
4
Biochemistry and Environmental Chemistry, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540139 Targu Mures, Romania
5
Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania
*
Authors to whom correspondence should be addressed.
Nutrients 2026, 18(1), 16; https://doi.org/10.3390/nu18010016
Submission received: 23 November 2025
/
Revised: 15 December 2025
/
Accepted: 17 December 2025
/
Published: 19 December 2025
(This article belongs to the Special Issue Dietary Patterns and Gut Microbiota)
Abstract
Background: Lower urinary tract infections (LUTIs) and irritable bowel syndrome (IBS) have been associated with histamine-producing gut dysbiosis, characterized by an overgrowth of histaminogenic bacteria and opportunistic fungi. This study examines the relationship between histaminogenic microbial imbalance, dietary factors, and LUTIs in women with IBS, emphasizing the potential nutritional contributions to microbiota modulation. Methods: A cohort of 188 women was evaluated by analyzing the intestinal microbiota associated with sporadic and recurrent lower urinary tract infections and irritable bowel syndrome, along with a questionnaire on risky eating behaviors. Results: Dysbiosis was associated with an overgrowth of histamine-producing bacteria (Escherichia coli, Enterobacter spp., Clostridium spp.) and Candida albicans, along with a depletion of protective taxa (Lactobacillus, Bifidobacterium). Dysbiosis, characterized by an increase in histamine-producing bacteria (Escherichia coli, Enterobacter spp., Clostridium spp.) and Candida albicans, together with a depletion of protective taxa (Lactobacillus, Bifidobacterium), has been associated with lower urinary tract infections and irritable bowel syndrome. Regarding the increase in histaminogenic flora, significant associations with dietary factors concerned only the frequent consumption of fast food. Conclusions: These findings highlight the role of histamine-driven dysbiosis in sustaining chronic inflammation and susceptibility to LUTIs and IBS, supporting microbiota modulation as a potential preventive and therapeutic strategy.
1. Introduction
Gut microbiota and systemic health. The intestinal microbiota plays a crucial role in maintaining digestive, metabolic, and immune homeostasis. Its imbalance, known as dysbiosis, has been increasingly associated with a wide spectrum of systemic disorders. Du et al. emphasized the influence of dietary habits on gut microbial composition and the indirect link with urinary tract infection (UTI) risk, suggesting that diet may modulate susceptibility to such infections through ecosystem-level microbial shifts [1]. Similarly, Dominoni et al. highlighted the interplay between the urogenital microbiota and the urothelial immune microenvironment, linking microbial alterations to recurrent cystitis [2]. Brigida et al. further proposed that modulation of the intestinal microbiome could serve as a therapeutic strategy for the prevention and management of recurrent UTIs [3]. In the context of irritable bowel syndrome (IBS), Shrestha et al. summarized evidence confirming the contribution of microbial imbalances to disease pathogenesis and symptom expression, supporting the hypothesis of a shared dysbiotic background between IBS and UTIs [4]. Recent urinary microbiome studies have also shown that alterations in bacterial communities may promote persistence and recurrence [5].
Histamine-producing bacteria. Histamine also plays a key role in regulating mucosal permeability and inflammation through the link between increased permeability and systemic inflammation driven by dysbiosis [6,7]. The expansion of histamine-producing bacterial populations, accompanied by the depletion of protective species, such as Lactobacillus and Bifidobacterium, can create a pro-inflammatory intestinal environment, and dietary interventions can significantly reduce the abundance of histamine-secreting bacteria [8].
Fungal dysbiosis. Overgrowth of Candida albicans has been described in the context of intestinal dysbiosis and is associated with inflammatory disorders and carcinogenesis [9,10]. Opportunistic fungi, together with histamine-producing bacteria, contribute to the maintenance of a dysbiotic intestinal environment that favors both symptoms related to irritable bowel syndrome and increased susceptibility to recurrent urinary tract infections.
Diet. Microbial metabolites derived from the diet can modulate intestinal metabolism and the synthesis of bioactive compounds, including histamine [11,12], with influence also on the serum metabolite profile, negatively impacting clinical parameters [13]. Nutritional factors can indirectly modulate the intestinal balance by altering the substrates available for bacterial fermentation and metabolism, thus affecting the production of bioactive metabolites such as histamine [11,12,13].
Consequently, exploring the interrelationship between diet, histaminogenic flora, and dysbiosis may provide novel insights for the prevention and integrated management of IBS and recurrent UTIs.
The aim of this study was to investigate the associations between intestinal microbiota composition (bacterial, fungal, and histaminogenic communities), dietary habits, and fluid intake in relation to the presence and recurrence of lower urinary tract infections (LUTIs) in women with irritable bowel syndrome (IBS), with particular focus on the role of opportunistic and histaminogenic microorganisms, fungi, and protective taxa such as Lactobacillus and Bifidobacterium.
2. Materials and Methods
Selection of the Study Group. Women aged 18–45 years were recruited from family medicine practices and private dietetics clinics in the Mureș region, Romania. Eligibility was based on a medical history of lower urinary tract infections (LUTIs) and willingness to provide stool and urine samples.
To investigate the associations between gut microbiota composition, lower urinary tract infections, and irritable bowel syndrome (IBS), participants were stratified into clinical subgroups as follows: women without a history of LUTIs or IBS (NLUTIs, NIBS); women with sporadic LUTIs (SLUTIs), defined as one or two symptomatic LUTI episodes within the previous 12 months; women with SLUTIs and NIBS; women with SLUTIs and IBS; and women with recurrent LUTIs (RLUTIs), characterized by at least three and up to more than six symptomatic LUTI episodes within the past 12 months. This stratification allowed the assessment of how lower urinary tract infections, with or without the presence of irritable bowel syndrome, are associated with intestinal dysbiosis.
Inclusion criteria were as follows: women aged 18–45 years, a documented history of lower urinary tract infection (LUTIs) confirmed by urine culture (for the LUTIs subgroups), availability of dietary and hydration data, and provision of written informed consent for biological sample collection. Only women were included in order to reduce variability related to sex-specific differences in the urogenital microbiota and to reflect the epidemiology of LUTIs, which predominantly affect otherwise healthy young women.
Exclusion criteria included recent use of antibiotics, probiotics, or antifungal agents within the previous 30 days; use of other medications potentially affecting microbiota (e.g., contraceptives, proton pump inhibitors); pregnancy or lactation; chronic gastrointestinal diseases; metabolic or endocrine disorders; renal or hepatic insufficiency; ongoing immunosuppressive therapy; or inability to provide informed consent. Medication use was assessed by self-report from participants.
- Questionnaires and Dietary Assessment
Dietary habits history was assessed using a structured questionnaire with a 5-point Likert scale (1 = strongly disagree, 5 = strongly agree). Participants reported consumption frequency for predefined food categories, with portion sizes standardized. Data allowed the association of dietary patterns with microbiota composition. Dietary intake was assessed using the shortened, validated version of the Rapid Eating Assessment for Participants (REAP-S) [14].
- Urinary Tract Infection Assessment
Data regarding lower urinary tract infections (LUTIs) were obtained from participants’ primary care medical records, based on laboratory urine analyses performed by certified clinical laboratories. LUTIs were considered confirmed if the medical records documented the presence of ≥103 colony-forming units (CFU)/mL of uropathogenic bacteria. These records were used to classify participants into groups with SLUTIs (<3 symptomatic episodes in the past 12 months) and recurrent RLUTIs (≥3 symptomatic episodes in the past 12 months).
- Irritable Bowel Syndrome Assessment
Women with a registered IBS diagnosis in primary care records, confirmed by a gastroenterology specialist using the Rome IV criteria, were included in the study.
- Microbiota Analysis
Fecal samples (1 g) were collected at least 7 days after the completion of any antibiotic therapy, stored at 2–8 °C, and processed within 5 days of collection. Culture-based analysis quantified pathogenic bacteria (Escherichia coli, Klebsiella spp., Enterobacter spp., Clostridium spp.), fungi (Candida spp.), and beneficial bacteria (Lactobacillus spp., Bifidobacterium spp.). Dysbiosis was assessed as mild (1–5), moderate (6–12), or severe (>12), with values ≥6 indicating clinically relevant dysbiosis. Microbiota analysis relied on culture-based methods, capturing only the cultivable fraction of the community (CCM). All procedures were performed by trained personnel in accordance with laboratory biosafety standards, and participant anonymity was strictly maintained.
The distribution of histaminogenic flora was further analyzed across clinical subgroups, including the entire study cohort, women with no lower urinary tract infections (LUTIs), sporadic LUTIs, recurrent LUTIs, and those with or without irritable bowel syndrome (IBS). Comparative analyses were also performed according to microbial and biochemical parameters, putrefactive flora, fecal pH, acidifying flora, and fungal counts to elucidate the interactions between gut microbial ecology and histamine metabolism. Normal parameters of histaminogenic flora were classified as NHF (normal histaminogenic flora), whereas elevated levels were classified as IHF (increased histaminogenic flora).
Statistical Analysis
The study database was created in Microsoft Excel 2021, and statistical analyses were performed using GraphPad Prism version 10. For continuous numerical variables, means and standard deviations were calculated, while categorical variables were summarized as counts and percentages. Associations between the presence of urinary tract infections (LUTIs) or irritable bowel syndrome (IBS) and the analyzed bacterial taxa were assessed using the chi-square test. In addition, logistic regression analyses were performed to identify associations between participants without LUTIs versus those with SLUTIs, between those with SLUTIs versus those with RLUTIs, and between those diagnosed with irritable bowel syndrome associated with SLUTIs and those without IBS.
A 95% confidence interval was applied, and p-values < 0.05 were considered statistically significant.
Ethical Considerations. The study was conducted between November 2022 and November 2023. All participants, recruited on a voluntary basis through family medicine and dietetics clinics, provided written informed consent. The protocol was approved by the local Ethics Committee and adhered to the Declaration of Helsinki.
3. Results
Of the 188 participating patients, 62.2% (n = 117) had sporadic lower urinary tract infections (SLUTIs), defined as 1–2 episodes in the past year; 27% (n = 52) had recurrent lower urinary tract infections (RLUTIs), defined as 3 or more episodes in the past year; and 10% (n = 19) reported no LUTIs during the past year. Among patients with SLUTIs, 40.1% (n = 47) also had irritable bowel syndrome (IBS).
Using culture-based methods, sporadic urinary tract infections were significantly associated with Escherichia coli (p = 0.0143), Bifidobacterium spp. (p < 0.0001), Lactobacillus spp. (p = 0.0203), Candida albicans (p < 0.0001), and Candida spp. (p < 0.0001), whereas no significant associations were observed for Klebsiella spp., Proteus spp., Enterobacter spp., Clostridium spp., or Geotrichum spp. (p > 0.05). Recurrent urinary tract infections were significantly associated only with Bifidobacterium spp. (p < 0.0001) (Table 1).
Logistic regression comparing SLUTI and NLUTI patients revealed significant associations with increased Escherichia coli (p = 0.0357) and Candida albicans (OR = 3.48, p = 0.0123) (Table 2).
Logistic regression showed that recurrent lower urinary tract infections (RLUTIs) were significantly associated only with reduced Lactobacillus spp. (OR = 1.78, p = 0.0228), while other microbial changes, including Escherichia coli, Klebsiella spp., Clostridium spp., Bifidobacterium spp., and Candida albicans, were not significant (Table 3).
In patients with SLUTIs and IBS, culture-based analysis (CCM) revealed significant differences for Escherichia coli (p < 0.0001), Enterobacter spp., Clostridium spp. (p = 0.006), Bifidobacterium spp. (p < 0.0001), Lactobacillus spp. (p = 0.0224), Candida albicans (p < 0.0001), and Candida spp. (p < 0.0001) (Table 4).
Statistical analysis revealed strong associations between histaminogenic flora and specific gut microbiota profiles. Significant differences were observed in the CCM for Escherichia coli (p < 0.0001), Klebsiella spp. (p < 0.0001), and Enterobacter spp. (p < 0.0001) (Table 5).
Statistical analysis revealed significant associations between elevated histaminogenic flora and intestinal fungal colonization. Significant differences were observed in the CCM for Candida albicans (p < 0.0001), Candida spp. (p < 0.0001), Geotrichum spp. (p < 0.0001), Molds (p = 0.0015), (Table 6).
Histaminogenic flora was not significantly associated with IBS (p = 0.7694) or urinary tract infections (p = 0.7690), but was significantly linked to alkaline fecal pH (p = 0.0001), putrefactive bacteria (p < 0.0001), and fungi (p = 0.001), suggesting a role in intestinal hyperhistaminemia (Table 7).
Logistic regression identified microbial factors associated with elevated histaminogenic flora, including alkaline fecal pH (OR = 4.01, p = 0.0232), reduced acidifying bacteria (Lactobacillus spp. and Bifidobacterium spp., OR = 1.82, p = 0.0232), and fungal overgrowth, particularly Candida spp. (OR = 3.98, p = 0.0024), suggesting that both bacterial and fungal imbalances contribute to histamine-producing microbiota (Table 8).
Except for frequent fast-food consumption (≥2 times/week, p = 0.0267), no significant associations were observed between dietary intake—including whole grains, vegetables, fruits, and water—and histaminogenic flora (Table 9).
4. Discussion
These findings are based on culture-dependent data, reflecting only the cultivable component of the microbiota (CCM). The results of this study support the hypothesis that both irritable bowel syndrome (IBS) and urinary tract infections (UTIs) are associated with complex patterns of intestinal dysbiosis [15,16,17]. SLUTIs were linked to an increased prevalence of enteric pathogens alongside a reduction in beneficial microbial taxa, suggesting that intestinal microbial imbalance may contribute to susceptibility to urinary infections. Logistic regression comparing patients with uncomplicated lower urinary tract infections (SLUTIs) to those without infection (NLUTIs) further indicated a broader dysbiotic signature, based on the cultivable component of the microbiota (CCM). Collectively, these results reinforce the concept that microbial dysbiosis plays a meaningful role in the pathogenesis of sporadic lower urinary tract infections. The significant association observed between RLUTIs and altered levels of Bifidobacterium spp. supports the hypothesis that disruption of protective commensal populations may predispose individuals to recurrent uropathogen colonization. Bifidobacterium spp. plays a key role in maintaining mucosal homeostasis, regulating immune responses, and producing short-chain fatty acids (SCFAs), which contribute to epithelial barrier integrity [18]. Consequently, a reduced abundance of these species may weaken host defense pathways and facilitate uropathogenic persistence.
In our study, individuals without lower urinary tract infections exhibited a more balanced intestinal microbiota, whereas those with sporadic infections showed more pronounced dysbiosis. However, the differences between individuals with sporadic and recurrent infections were less marked. One plausible interpretation is that participants who currently experience only sporadic episodes may already have a microbial imbalance that could, over time, increase their susceptibility to more frequent infections. In this context, persistent dysbiosis may represent an intermediate stage between occasional LUTIs and the progression toward recurrent infection patterns.
In irritable bowel syndrome, opportunistic and histamine-producing bacteria, including Escherichia coli, Enterobacter spp. and Clostridium spp., along with fungal overgrowth (Candida albicans, Candida spp.), were shown to be increased within the CCM, while protective species such as Bifidobacterium spp. and Lactobacillus spp. were reduced, indicating an imbalance between commensal and pathogenic microbiota, which may promote mucosal inflammation and gastrointestinal symptoms, consistent with recent evidence on histamine-producing bacteria in visceral hyperalgesia and intestinal inflammation [19,20].
The strong associations identified between histaminogenic flora and specific gut microbiota profiles suggest a relevant microbial signature linked to increased histamine-producing capacity. The significant differences observed for Escherichia coli, Klebsiella spp., and Enterobacter spp. indicate that overgrowth of these taxa may contribute to a pro-inflammatory intestinal environment through enhanced histamine generation or through metabolic pathways that promote mucosal irritation. Many of these genera are known to include opportunistic pathobionts capable of producing biogenic amines or altering epithelial permeability, which may exacerbate histamine-related symptoms and influence host immune responses. These findings align with emerging evidence linking dysbiosis, altered nitrogen metabolism, and heightened histamine activity in conditions such as IBS, food intolerances, and low-grade gut inflammation. Importantly, the results highlight the potential clinical relevance of targeting histaminogenic microbial populations through dietary strategies, prebiotics, or microbiota-modulating interventions aimed at restoring metabolic balance, confirming prior studies on their role in increasing intestinal permeability and systemic inflammation [21,22].
Candida albicans, Candida spp., Geotrichum spp. and Molds were consistently associated with histaminogenic flora, emphasizing bacteria–fungi interactions in maintaining a pro-inflammatory gut environment. These findings indicate that elevated histaminogenic flora is strongly associated not only with histamine-producing bacteria but also with overgrowth of opportunistic fungal species. This fungal overrepresentation may exacerbate mucosal inflammation and contribute to dysregulated histamine metabolism in the gut, potentially amplifying intestinal barrier dysfunction and inflammatory responses [23,24,25,26].
Fecal pH may also influence microbiota composition and metabolic responses, with histaminogenic flora associated with an alkaline pH, increased putrefactive bacteria, and fungal presence, suggesting that bacterial metabolism and local intestinal conditions may favor histamine accumulation [27].
Mechanistic Implications. The interplay between histamine-producing bacteria and Candida albicans likely contributes to chronic intestinal inflammation, IBS symptomatology, and UTI recurrence. These findings align with recent evidence highlighting the role of complex bacteria–fungi interactions and histamine-producing bacteria in gastrointestinal and extraintestinal disease pathogenesis [28].
The results underscore the central role of intestinal acid-base balance and microbial composition in regulating histaminogenic flora. An alkaline fecal pH, resulting from enhanced proteolytic metabolism of putrefactive bacteria, generates ammonia, biogenic amines, and alkaline metabolites that favor the growth of histamine-producing bacteria. A reduction in acidifying bacteria (Lactobacillus spp. and Bifidobacterium spp.) decreases the production of organic acids (e.g., lactic, acetic, propionic), which normally maintain a slightly acidic intestinal environment and inhibit pathogenic overgrowth. This loss of protective function promotes dysbiosis and the expansion of decarboxylase-active bacteria involved in histamine metabolism. Fungal overgrowth, particularly Candida albicans, further contributes to imbalance by producing alkaline metabolites, consuming fermentable sugars, competing with beneficial bacteria, and indirectly activating inflammatory immune pathways that increase intestinal permeability and histamine absorption. Clinically, these findings suggest that elevated histaminogenic flora reflects complex intestinal dysbiosis, where the interplay between proteolytic bacteria, fungal overgrowth, and depletion of acidifying taxa disrupts intestinal homeostasis. Overall, the logistic regression model indicates that dysbiosis characterized by intestinal alkalinization, reduced acidifying bacteria, and increased fungal load is closely associated with the proliferation of histaminogenic microbiota.
Emerging evidence suggests that alterations in histaminogenic gut flora may not only influence intestinal homeostasis but could also be linked to metabolic disorders, highlighting the potential systemic impact of dysbiosis [29,30,31].
Among all dietary factors assessed, only frequent fast-food consumption, particularly among younger population groups [32], emerged as being associated with elevated histaminogenic flora, whereas inadequate intake of whole grains, vegetables, fruits, or water showed no meaningful relationship with histamine-producing microbial profiles. Direct evidence linking water intake to histaminogenic flora is lacking, but previous studies suggest that both water source and hydration status can influence gut microbial composition and homeostasis, which may indirectly affect the abundance of histamine-producing bacteria [33,34,35].
Recent literature indicates that dietary factors may indirectly affect microbiota and bioactive metabolite production, including histamine, through modulation of fermentation substrates [36]. Accumulating evidence indicates that high-fat diets [35], processed foods, and dietary patterns characteristic of fast-food consumption can disrupt gut microbial homeostasis in ways that may promote the expansion of opportunistic or metabolically active taxa, including bacteria capable of producing biogenic amines such as histamine [36,37,38].
4.1. Future Directions
Further research should incorporate advanced sequencing and metabolomics to clarify causal relationships between diet, microbiota, and recurrence risk. Establishing safe thresholds for dietary bioactive amines, along with improving databases on food composition and water intake, is essential for the prevention and integrated management of IBS and recurrent UTIs. Additionally, future studies should employ more detailed dietary assessment tools to examine the broader effects of diet on microbiota composition and related health outcomes and should also carefully control for medication use, given its potential impact on microbiota structure.
Overall, IBS and recurrent LUTIs share a dysbiotic environment dominated by histamine-producing bacteria and Candida albicans, promoting chronic inflammation, immune imbalance, and susceptibility to recurrence, emphasizing the clinical relevance of microbiota-targeted interventions.
4.2. Limitations
This study did not measure histamine or DAO levels, and microbiota assessment relied solely on culture-based methods, which capture only the cultivable fraction of the flora. Dietary data were obtained through a rapid-screening questionnaire (REAP-S), limiting detailed nutritional analysis. Medication use was based on self-report, although participants using antibiotics or other microbiota-modifying drugs were excluded.
5. Conclusions
These conclusions are derived from culture-dependent data and therefore reflect only the cultivable component of the microbiota (CCM). In this observational study, lower urinary tract infections (LUTIs) and irritable bowel syndrome (IBS) were associated with an increased presence of histaminogenic flora, characterized by histamine-producing bacteria (e.g., Escherichia coli, Klebsiella spp., Enterobacter spp.) and fungi (Candida albicans), alongside a reduced presence of microorganisms commonly regarded as beneficial, such as Lactobacillus and Bifidobacterium. This microbial pattern was associated with an alkaline fecal pH and increased prevalence of putrefactive bacteria. While general dietary patterns and fluid intake showed limited associations, frequent fast-food consumption was associated with higher levels of histaminogenic flora. Associations observed in this study suggest that strategies supporting beneficial microbiota—such as prebiotics, probiotics, and dietary components favoring Lactobacillus and Bifidobacterium—may be relevant for the management of IBS and recurrent LUTIs, although causal relationships cannot be inferred from these data.
Author Contributions
Conceptualization, F.R. and E.M.; methodology, F.R.; software, C.A.; validation, F.R. and E.M.; formal analysis, C.A.; investigation, R.M.; resources, C.F.; data curation, C.A.; writing—original draft preparation, F.R.; writing—review and editing, C.F. and R.M.; visualization, S.N.; supervision, F.R. and S.N.; project administration, E.M.; funding acquisition, F.R. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of “George Emil Palade” University of Medicine, Pharmacy, Science and Technology of Targu Mures, Romania nr. 2062, date of approval 9 February 2023.
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Conflicts of Interest
The authors declare no conflicts of interest.
References
- Du, Y.; Sui, X.; Bai, Y.; Shi, Z.; Liu, B.; Zheng, Z.; Zhang, Z.; Zhao, Y.; Wang, M.; Sun, H.; et al. Dietary influences on urinary tract infections: Unraveling the gut microbiota connection. Food Funct. 2024, 15, 10099–10109. [Google Scholar] [CrossRef] [Scilit]
- Dominoni, M.; Scatigno, A.L.; La Verde, M.; Bogliolo, S.; Melito, C.; Gritti, A.; Pasquali, M.F.; Torella, M.; Gardella, B. Microbiota Ecosystem in Recurrent Cystitis and the Immunological Microenvironment of Urothelium. Healthcare 2023, 11, 525. [Google Scholar] [CrossRef] [Scilit]
- Brigida, M.; Saviano, A.; Petruzziello, C.; Manetti, L.L.; Migneco, A.; Ojetti, V. Gut Microbiome Implication and Modulation in the Management of Recurrent Urinary Tract Infection. Pathogens 2024, 13, 1028. [Google Scholar] [CrossRef] [Scilit]
- Shrestha, B.; Patel, D.; Shah, H.; Hanna, K.S.; Kaur, H.; Alazzeh, M.S.; Thandavaram, A.; Channar, A.; Purohit, A.; Venugopal, S. The Role of Gut-Microbiota in the Pathophysiology and Therapy of Irritable Bowel Syndrome: A Systematic Review. Cureus 2022, 14, e28064. [Google Scholar] [CrossRef] [Scilit]
- Kim, D.S.; Lee, J.W. Urinary Tract Infection and Microbiome. Diagnostics 2023, 13, 1921. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- De Palma, G.; Shimbori, C.; Reed, D.E.; Yu, Y.; Rabbia, V.; Lu, J.; Jimenez-Vargas, N.; Sessenwein, J.; Lopez-Lopez, C.; Pigrau, M.; et al. Histamine production by the gut microbiota induces visceral hyperalgesia through histamine 4 receptor signaling in mice. Sci. Transl. Med. 2022, 14, eabj1895. [Google Scholar] [CrossRef] [Scilit]
- Al-Maamari, A.; Sultan, M.Ș.; Ding, S.Ș.; Yuxin, D.; Wang, M.Y.; Su, S. Mechanisms and implications of histamine-induced reactions and complications. Allergol. Immunopathol. 2025, 53, 122–139. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Sánchez-Pérez, S.; Comas-Basté, O.; Costa-Catala, J.; Iduriaga-Platero, I.; Veciana-Nogués, M.T.; Vidal-Carou, M.C.; Latorre-Moratalla, M.L. The Rate of Histamine Degradation by Diamine Oxidase Is Compromised by Other Biogenic Amines. Front. Nutr. 2022, 9, 897028. [Google Scholar] [CrossRef] [Scilit]
- Dong, L.; Zhang, C.; Xu, J. Unveiling the overlooked fungi: The vital role of gut fungi in inflammatory bowel disease and colorectal cancer. Gut Pathog. 2024, 16, 12. [Google Scholar] [CrossRef] [Scilit]
- Jawhara, S. How gut bacterial dysbiosis can promote Candida albicans overgrowth during colonic inflammation. Microorganisms 2022, 10, 1014. [Google Scholar] [CrossRef] [Scilit]
- Singh, P.; Grabauskas, G.; Zhou, S.Y.; Gao, J.; Zhang, Y.; Owyang, C. High FODMAP diet causes barrier loss via lipopolysaccharide-mediated mast cell activation. JCI Insight 2021, 6, e146529. [Google Scholar] [CrossRef] [Scilit]
- Prasain, J.; Barnes, S. Recent updates on diet-derived gut microbial metabolites. eFood 2024, 5, e181. [Google Scholar] [CrossRef] [Scilit]
- Zhang, J.; Qi, H.; Li, M.; Wang, Z.; Jia, X.; Sun, T.; Du, S.; Su, C.; Zhi, M.; Du, W.; et al. Diet Mediate the Impact of Host Habitat on Gut Microbiome and Influence Clinical Indexes by Modulating Gut Microbes and Serum Metabolites. Adv. Sci. 2024, 11, e2310068. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Segal-Isaacson, C.J.; Wylie-Rosett, J.; Gans, K.M. Validation of a short dietary assessment questionnaire: The Rapid Eating and Activity Assessment for Participants short version (REAP-S). Diabetes Educ. 2004, 30. [Google Scholar] [CrossRef] [Scilit]
- Ruța, F.; Avram, C.; Mardale, E.; Pribac, M.; Suciu, S.; Nyulas, V. A Perspective on the Interaction Between Recurrent Lower Urinary Tract Infections and Irritable Bowel Syndrome. Nutrients 2024, 16, 3613. [Google Scholar] [CrossRef] [Scilit]
- Ruța, F.; Pribac, M.; Mardale, E.; Suciu, S.; Maior, R.; Bogdan, S.; Avram, C. Associations between Gut Microbiota Dysbiosis and Other Risk Factors in Women with a History of Urinary Tract Infections. Nutrients 2024, 16, 1753. [Google Scholar] [CrossRef] [Scilit]
- Iqbal, Z.S.; Halkjær, S.I.; Ghathian, K.S.A.; Heintz, J.E.; Petersen, A.M. The Role of the Gut Microbiome in Urinary Tract Infections: A Narrative Review. Nutrients 2024, 16, 3615. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Gavzy, S.J.; Kensiski, A.; Lee, Z.L.; Mongodin, E.F.; Ma, B.; Bromberg, J.S. Bifidobacterium mechanisms of immune modulation and tolerance. Gut Microbes 2023, 15, 2291164. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ross, T.; Pujo, J.; Hall-Bruce, M.; Collins, S.; Vanner, S.; Reed, D.E.; Bercik, P.; De Palma, G. A189 investigating the role of bacterial histamine metabolism in visceral hyperalgesia. J. Can. Assoc. Gastroenterol. 2024, 7, 148–149. [Google Scholar] [CrossRef] [Scilit]
- Di Vincenzo, F.; Del Gaudio, A.; Petito, V.; Lopetuso, L.R.; Scaldaferri, F. Gut microbiota, intestinal permeability, and systemic inflammation: A narrative review. Intern. Emerg. Med. 2024, 19, 275–293. [Google Scholar] [CrossRef] [Scilit]
- Khatouf, R.; Dahani, S.; Hariri, O.E.; Amiyare, R.; Bouchriti, N. Microbiological profile and prevalence of histamine-producing bacteria in fresh sardines stored at different temperatures. Vet. World 2024, 17, 2376–2384. [Google Scholar] [CrossRef] [Scilit]
- Sánchez-Pérez, S.; Comas-Basté, O.; Duelo, A.; Veciana-Nogués, M.T.; Berlanga, M.; Latorre-Moratalla, M.L.; Vidal-Carou, M.C. Intestinal Dysbiosis in Patients with Histamine Intolerance. Nutrients 2022, 14, 1774. [Google Scholar] [CrossRef] [Scilit]
- Valitutti, F.; Mennini, M.; Monacelli, G.; Fagiolari, G.; Piccirillo, M.; Di Nardo, G.; Di Cara, G. Intestinal permeability, food antigens and the microbiome: A multifaceted perspective. Front. Allergy 2025, 5, 1505834. [Google Scholar] [CrossRef] [Scilit]
- Zaongo, S.D.; Ouyang, J.; Isnard, S.; Zhou, X.; Harypursat, V.; Cui, H.; Routy, J.P.; Chen, Y. Candida albicans can foster gut dysbiosis and systemic inflammation during HIV infection. Gut Microbes 2023, 5, 2167171. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kumamoto, C.A.; Gresnigt, M.S.; Hube, B. The gut, the bad and the harmless: Candida albicans as a commensal and opportunistic pathogen in the intestine. Curr. Opin. Microbiol. 2020, 56, 7–15. [Google Scholar] [CrossRef] [Scilit]
- Brinck, J.E.; Sinha, A.K.; Laursen, M.F.; Dragsted, L.O.; Raes, J.; Uribe, R.V.; Walter, J.; Roager, H.M.; Licht, T.R. Intestinal pH: A major driver of human gut microbiota composition and metabolism. Nat. Rev. Gastroenterol. Hepatol. 2025, 22, 639–656. [Google Scholar] [CrossRef] [Scilit]
- Ryodai, Y.; Inoue, K.Y.; Nishino, K.; Yamasaki, S. Intestinal and fecal pH in human health. Front. Microbiomes 2023, 2, 1192316. [Google Scholar] [CrossRef] [Scilit]
- Fiorani, M.; Del Vecchio, L.E.; Dargenio, P.; Kaitsas, F.; Rozera, T.; Porcari, S.; Gasbarrini, A.; Cammarota, G.; Ianiro, G. Histamine-producing bacteria and their role in gastrointestinal disorders. Expert Rev. Gastroenterol. Hepatol. 2023, 17, 709–718. [Google Scholar] [CrossRef] [Scilit]
- Bandopadhyay, P.; Ganguly, D. Gut dysbiosis and metabolic diseases. Prog. Mol. Biol. Transl. Sci. 2022, 191, 153–174. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Hamjane, N.; Mechita, M.B.; Nourouti, N.G.; Barakat, A. Gut microbiota dysbiosis -associated obesity and its involvement in cardiovascular diseases and type 2 diabetes. A systematic review. Microvasc. Res. 2024, 151, 104601. [Google Scholar] [CrossRef] [Scilit]
- Bucurica, S.; Nancoff, A.S.; Dutu, M.; Mititelu, M.R.; Gaman, L.E.; Ioniță-Radu, F.; Jinga, M.; Maniu, I.; Ruța, F. Exploring the Relationship between Lipid Profile, Inflammatory State and 25-OH Vitamin D Serum Levels in Hospitalized Patients. Biomedicines 2024, 12, 1686. [Google Scholar] [CrossRef] [Scilit]
- Bacârea, A.; Tarcea, M.; Boţianu, P.V.; Ruţa, F.; Bacârea, V. Age cut-off for type 2 diabetes mellitus screening amongst young adults from Mures District, Romania—A pilot study. Obes. Res. Clin. Pract. 2015, 9, 527–530. [Google Scholar] [CrossRef] [Scilit]
- Vanhaecke, T.; Bretin, O.; Poirel, M.; Tap, J. Drinking Water Source and Intake Are Associated with Distinct Gut Microbiota Signatures in US and UK Populations. J. Nutr. 2022, 152, 171–182. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
- Sato, K.; Hara-Chikuma, M.; Yasui, M.; Inoue, J.; Kim, Y.G. Sufficient water intake maintains the gut microbiota and immune homeostasis and promotes pathogen elimination. iScience 2024, 27, 109903. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
- Ruta, F.; Avram, C.; Raluca Maior, R. Physico-Chemical and Microbiological Differences between Mains and Bottled Water, in an Area in the Central Area of Romania. Int. J. Environ. Res. Public Health 2023, 20, 1115. [Google Scholar] [CrossRef] [Scilit]
- Shi, Z. Gut Microbiota: An Important Link between Western Diet and Chronic Diseases. Nutrients 2019, 11, 2287. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
- Sánchez-Pérez, S.; Comas-Basté, O.; Duelo, A.; Veciana-Nogués, M.T.; Berlanga, M.; Vidal-Carou, M.C.; Latorre-Moratalla, M.L. The dietary treatment of histamine intolerance reduces the abundance of some histamine-secreting bacteria of the gut microbiota in histamine intolerant women. A pilot study. Front. Nutr. 2022, 9, 1018463. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kim, S.J.; Kim, S.E.; Kim, A.R.; Kang, S.; Park, M.Y.; Sung, M.K. Dietary fat intake and age modulate the composition of the gut microbiota and colonic inflammation in C57BL/6J mice. BMC Microbiol. 2019, 19, 193. [Google Scholar] [CrossRef] [Scilit]
Table 1.
Relationship Between Gut Microbiota and Clinical LUTI Subgroups: absence of LUTIs, sporadic, and recurrent.
Table 1.
Relationship Between Gut Microbiota and Clinical LUTI Subgroups: absence of LUTIs, sporadic, and recurrent.
| Bacterial Populations | Microorganisms | LUTIs | p-Value | LUTIs | p-Value | ||
|---|---|---|---|---|---|---|---|
| NLUTIs (n = 19) | SLUTIs (n = 117) | SLUTIs (n = 117) | RLUTIs (n = 52) | ||||
| Putrefactive flora | Escherichia coli | 0.0143 | 0.5026 | ||||
| 4 (21.05%) | 6 (5.12%) | 6 (5.12%) | 1 (1.92%) | |||
| 13 (68.42%) | 107 (91.45%) | 107 (91.45%) | 48 (92.30%) | |||
| 2 (10.52%) | 4 (3.41%) | 4 (3.41%) | 3 (5.76%) | |||
| Proteus spp. | 0.5836 | 0.6677 | |||||
| 1 (5.26%) | 112 (95.72%) | 112 (95.72%) | 51 (98.07%) | |||
| 17 (89.47%) | 5 (4.27%) | 5 (4.27%) | 1 (1.92%) | |||
| Klebsiella spp. | 0.297 | 0.6727 | |||||
| 17 (89.47%) | 99 (84.61%) | 99 (84.61%) | 46 (76.92%) | |||
| 2 (10.52%) | 18 (15.38%) | 18 (15.38%) | 6 (11.53%) | |||
| Enterobacter spp. | 0.197 | 0.9952 | |||||
| 17 (89.47%) | 103 (88.03%) | 103 (88.03%) | 43 (82.69%) | |||
| 2 (10.52%) | 13 (11.11%) | 13 (11.11%) | 8 (15.38%) | |||
| 0 (0%) | 1 (0.85%) | 1 (0.85%) | 1 (1.92%) | |||
| Clostridium spp. | 0.2862 | 0.4286 | |||||
| 18 (94.73%) | 106 (90.59%) | 106 (90.59%) | 47 (90.38%) | |||
| 0 (0%) | 8 (6.83%) | 8 (6.83%) | 5 (9.61%) | |||
| 1 (5.26%) | 3 (2.56%) | 3 (2.56%) | 0 (0%) | |||
| Acidifying flora | Bifidobacterium spp. | <0.0001 | <0.0001 | ||||
| 14 (73.68%) | 20 (17.09%) | 20 (17.09%) | 1 (1.92%) | |||
| 5 (26.31%) | 0 (0%) | 0 (0%) | 11 (21.15%) | |||
| 0 (0%) | 97 (82.90%) | 97 (82.90%) | 40 (76.92%) | |||
| Lactobacillus spp. | 0.0203 | 0.1508 | |||||
| 6 (31.57%) | 58 (49.57%) | 58 (49.57%) | 20 (38.46%) | |||
| 1 (5.26%) | 0 (0%) | 0 (0%) | 1 (1.92%) | |||
| 12 (63.15%) | 59 (50.42%) | 59 (50.42%) | 31 (59.61%) | |||
| Yeasts | Candida albicans | <0.0001 | 0.6206 | ||||
| 17 (89.47%) | 33 (28.20%) | 33 (28.20%) | 13 (25%) | |||
| 2 (10.52%) | 82 (70.08%) | 82 (70.08%) | 39 (75%) | |||
| Candida spp. | <0.0001 | 0.9677 | |||||
| 17 (89.47%) | 22 (18.80%) | 22 (18.80%) | 10 (19.20%) | |||
| 2 (10.52%) | 94 (80.34%) | 94 (80.34%) | 42 (80.76) | |||
| Geotrichum spp. | 0.594 | 0.9845 | |||||
| 15 (78.94%) | 103 (88.03%) | 103 (88.03%) | 45 (86.53%) | |||
| 4 (21.05%) | 14 (11.96%) | 14 (11.96%) | 7 (13.46%) | |||
Table 2.
Association Between Microbiota Alterations and the Risk of Sporadic Lower Urinary Tract Infections (SLUTIs): Logistic Regression Analysis.
Table 2.
Association Between Microbiota Alterations and the Risk of Sporadic Lower Urinary Tract Infections (SLUTIs): Logistic Regression Analysis.
| Variables | NLUTIs vs. SLUTIs | ||
|---|---|---|---|
| OR | 95% CI | p-Value | |
| Increased Escherichia coli | 1.7822 | 1.2640 to 2.3179 | 0.0357 |
| Increased Klebsiella spp. | 1.4481 | 0.2875 to 7.2922 | 0.8686 |
| Increased Clostridium spp. | 0.9287 | 0.1205 to 7.1589 | 0.9133 |
| Decreased Lactobacillus_spp. | 0.7208 | 0.4149 to 1.2523 | 0.1727 |
| Decreased Bifidobacterium spp. | 0.7360 | 0.4054 to 1.3361 | 0.3136 |
| Increased Candida_albicans | 3.6587 | 2.7872 to 17.0044 | 0.0123 |
Table 3.
Association Between Microbiota Alterations and the Risk of Recurrent Lower Urinary Tract Infections (RLUTIs): Logistic Regression Analysis.
Table 3.
Association Between Microbiota Alterations and the Risk of Recurrent Lower Urinary Tract Infections (RLUTIs): Logistic Regression Analysis.
| Variables | NLUTIs vs. SLUTIs | ||
|---|---|---|---|
| OR | 95% CI | p-Value | |
| Increased Escherichia coli | 2.1616 | 1.9647 to 4.8433 | 0.0611 |
| Increased Klebsiella spp. | 0.7015 | 0.2506 to 1.9635 | 0.4996 |
| Increased Clostridium_spp. | 1.1065 | 0.3716 to 3.2946 | 0.8557 |
| Decreased Lactobacillus_spp. | 1.7796 | 1.5520 to 3.1011 | 0.0228 |
| Decreased Bifidobacterium spp. | 1.0828 | 0.7100 to 1.6514 | 0.7117 |
| Increased Candida_albicans | 0.6347 | 0.3042 to 1.3243 | 0.2257 |
Table 4.
Associations Between Sporadic LUTIs in Women with IBS and Gut Microbiota Composition.
| Bacterial Populations | Microorganisms | SLUTI-IBS | p-Value | |
|---|---|---|---|---|
| SLUTI-NIBS (n = 70) | SLUTI-IBS (n = 47) | |||
| Putrefactive flora | Escherichia coli | <0.0001 | ||
| 51 (72.85%) | 10 (21.27%) | ||
| 18 (25.71%) | 36 (76.59%) | ||
| 1 (1.42%) | 1 (2.12%) | ||
| Proteus spp. | 0.645 | |||
| 70 (100%) | 43 (91.48%) | ||
| 0 (0%) | 4 (8.51%) | ||
| Klebsiella spp. | 0.297 | |||
| 60 (85.71%) | 40 (85.10%) | ||
| 10 (1.42%) | 7 (14.89%) | ||
| Enterobacter spp. | 0.008 | |||
| 63 (90%) | 41 (87.23%) | ||
| 7 (10%) | 5 (10.63%) | ||
| 0 (0%) | 1 (2.12%) | ||
| Clostridium spp. | 0.006 | |||
| 65 (92.85%) | 44 (93.61%) | ||
| 4 (5.71%) | 3 (6.38%) | ||
| 1 (1.42%) | 0 (0%) | ||
| Acidifying flora | Bifidobacterium spp. | <0.0001 | ||
| 60 (85.71%) | 23 (48.93%) | ||
| 1 (1.42%) | 0 (0%) | ||
| 9 (12.85%) | 24 (51.06%) | ||
| Lactobacillus spp. | 0.0224 | |||
| 36 (511.42%) | 17 (36.17%) | ||
| 5 (7.14%) | 0 (0%) | ||
| 29 (41.42%) | 30 (63.82%) | ||
| Yeasts | Candida albicans | <0.0001 | ||
| 49 (70%) | 15 (31.91%) | ||
| 21 (30%) | 32 (68.08%) | ||
| Candida spp. | <0.0001 | |||
| 54 (77.14%) | 6 (12.76%) | ||
| 16 (22.85%) | 41 (87.23%) | ||
| Geotrichum spp. | 0.154 | |||
| 66 (94.28%) | 26 (55.31%) | ||
| 4 (57.14%) | 19 (40.42%) | ||
Table 5.
Bacterial species distribution across different levels of histaminogenic flora.
| Microorganisms | Histaminogenic Flora | p-Value | |
|---|---|---|---|
| NHF (n = 36) | IHF (n = 152) | ||
| Escherichia coli | <0.0001 | ||
| 28 (77.77%) | 9 (59.21%) | |
| 2 (5.55%) | 142 (93.42%) | |
| 4 (11.11%) | 3 (1.97%) | |
| Klebsiella spp. | <0.0001 | ||
| 35 (97.22%) | 107 (70.39%) | |
| 0 (0%) | 46 (30.26%) | |
| Enterobacter spp. | <0.0001 | ||
| 34 (94.44%) | 106 (69.73%) | |
| 0 (0%) | 48 (31.57%) | |
| Proteus spp. | 0.9999 | ||
| 33 (91.66%) | 147 (96.71%) | |
| 1 (2.77%) | 5 (3.28%) | |
| Clostridium spp. | 0.2759 | ||
| 34 (94.44%) | 144 (94.73) | |
| 1 (2.77%) | 7 (4.60%) | |
| 1 (2.77%) | 1 (0.65%) | |
Table 6.
Fungal species distribution across different levels of histaminogenic flora.
| Microorganisms | Histaminogenic Flora | p-Value | |
|---|---|---|---|
| NHF (n = 36) | IHF(n = 152) | ||
| Candida albicans | <0.0001 | ||
| 30 (83.33%) | 48 (31.57%) | |
| 1 (2.77%) | 105 (69.07%) | |
| 1 (2.77%) | 1 (0.65%) | |
| Candida spp. | <0.0001 | ||
| 21 (58.33%) | 36 (23.36%) | |
| 6 (16.66%) | 125 (82.23%) | |
| Geotrichum spp. | <0.0001 | ||
| 35 (97.22%) | 112 (73.68%) | |
| 1 (2.77%) | 40 (26.31%) | |
| Molds | 0.0015 | ||
| 34 (94.44%) | 116 (76.31%) | |
| 1 (2.77%) | 37 (24.32%) | |
Table 7.
Distribution of histaminogenic flora across clinical and microbial parameters.
| Microorganisms | Histaminogenic Flora | p-Value | |
|---|---|---|---|
| NHF (n = 36) | IHF (n = 152) | ||
| IBS | 0.7694 | ||
| 26 (72.22%) | 106 (69.73%) | |
| 10 (27.77%) | 46 (30.26%) | |
| LUTIs (SLUTIs and RLUTIs) | 0.7690 | ||
| 4 (11.11%) | 15 (9.86%) | |
| 32 (88.88%) | 133 (87.5%) | |
| Fecal pH fecal | 0.0001 | ||
| 26 (72.22%) | 61 (40.13%) | |
| 8 (22.22%) | 93 (61.18%) | |
| Increased putrefactive flora | <0.0001 | ||
| 33 (91.66%) | 0 (0%) | |
| 1 (2.77%) | 152 (100%) | |
| Decreased acidifying flora | 0.050 | ||
| 9 (25) | 18 (11.84) | |
| 15 (41.66) | 144 (94.73) | |
| Yeasts | 0.001 | ||
| 25 (69.44%) | 62 (40.78%) | |
| 9 (25%) | 90 (59.21%) | |
Table 8.
Microbial Factors Associated with Increased Histaminogenic Flora: Logistic Regression Results.
Table 8.
Microbial Factors Associated with Increased Histaminogenic Flora: Logistic Regression Results.
| Variables | Increased Histaminogenic Flora | ||
|---|---|---|---|
| OR | 95% CI | p-Value | |
| Alkaline fecal pH (increased putrefactive flora) | 4.0062 | 1.6499 to 9.7280 | 0.0232 |
| Decreased acidifying flora | 1.8159 | 1.0851 to 3.0391 | 0.0232 |
| Increased yeast flora | 3.9817 | 1.6310 to 9.7204 | 0.0024 |
Table 9.
Associations between dietary intake and histaminogenic flora levels.
| Dietary Intake | Histaminogenic Flora | p-Value | |
|---|---|---|---|
| NHF (n = 36) | IHF (n = 152) | ||
| Fewer than 3 servings of whole grains per day | 0.084 | ||
| 17 (47.22%) | 50 (32.89%) | |
| 7 (19.44%) | 32 (21.05%) | |
| 3 (8.33%) | 39 (25.65%) | |
| 1 (2.77%) | 12 (7.89%) | |
| 5 (13.88%) | 20 (13.15%) | |
| Fewer than 3 servings of vegetables (excluding potatoes) per day | 0.614 | ||
| 9 (25%) | 45 (29.60%) | |
| 6 (16.66%) | 25 (16.44%) | |
| 12 (33.33%) | 36 (23.68%) | |
| 3 (8.33%) | 18 (11.84%) | |
| 5 (13.88%) | 27 (17.76%) | |
| Fewer than 2 servings of fruit per day | 0.684 | ||
| 9 (25%) | 49 (32.23%) | |
| 10 (27.77%) | 28 (52.63%) | |
| 6 (16.66%) | 35 (23.02%) | |
| 6 (16.66%) | 11 (7.23%) | |
| 6 (16.66%) | 28 (18.42%) | |
| Fast food consumption twice a week or more | 0.0267 | ||
| 23 (63.88%) | 99 (65.13) | |
| 5 (13.88%) | 6 (3.94) | |
| 4 (11.11%) | 11 (7.23) | |
| 1 (2.77%) | 21 (13.81) | |
| 1 (2.77%) | 17 (11.18) | |
| Less than 1 L of water per day | 0.924 | ||
| 18 (50%) | 71 (46.71%) | |
| 2 (5.55%) | 12 (7.89%) | |
| 6 (16.66%) | 27 (17.76%) | |
| 2 (5.55%) | 14 (9.21%) | |
| 6 (16.66%) | 22 (14.47%) | |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
MDPI and ACS Style
Ruța, F.; Avram, C.; Mardale, E.; Maior, R.; Filip, C.; Nemeth, S. Histamine-Producing Intestinal Dysbiosis and Its Role in Lower Urinary Tract Infections and Irritable Bowel Syndrome in Young Women. Nutrients 2026, 18, 16. https://doi.org/10.3390/nu18010016
AMA Style
Ruța F, Avram C, Mardale E, Maior R, Filip C, Nemeth S. Histamine-Producing Intestinal Dysbiosis and Its Role in Lower Urinary Tract Infections and Irritable Bowel Syndrome in Young Women. Nutrients. 2026; 18(1):16. https://doi.org/10.3390/nu18010016
Chicago/Turabian StyleRuța, Florina, Călin Avram, Elena Mardale, Raluca Maior, Cristina Filip, and Sebastian Nemeth. 2026. "Histamine-Producing Intestinal Dysbiosis and Its Role in Lower Urinary Tract Infections and Irritable Bowel Syndrome in Young Women" Nutrients 18, no. 1: 16. https://doi.org/10.3390/nu18010016
APA StyleRuța, F., Avram, C., Mardale, E., Maior, R., Filip, C., & Nemeth, S. (2026). Histamine-Producing Intestinal Dysbiosis and Its Role in Lower Urinary Tract Infections and Irritable Bowel Syndrome in Young Women. Nutrients, 18(1), 16. https://doi.org/10.3390/nu18010016
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
